Last reviewed · How we verify
NCT06796634
Effects of Cold Atmospheric Plasma (CAP) on Peritoneal Tumor Tissue
NA trial testing J-plasma in Cold Atmospheric Plasma (CAP) in 5 participants. Currently enrolling.
1 April 2025
Quick facts
| Lead sponsor | University Hospital, Ghent |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 5 |
| Start date | 21 August 2024 |
| Primary completion | 1 April 2025 |
| Estimated completion | 1 April 2025 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- J-plasma
Conditions studied
- Cold Atmospheric Plasma (CAP) — all drugs for Cold Atmospheric Plasma (CAP) →
- J-Plasma — all drugs for J-Plasma →
- Peritoneal Tumor — all drugs for Peritoneal Tumor →
Sponsor
University Hospital, Ghent
Who can join
18 and older, any sex, with Cold Atmospheric Plasma (CAP) or J-Plasma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There are to date no studies available that have examined the effects of CAP on tumor tissue in patients. The aim of this study is to investigate these effects in patients undergoing surgery for peritoneal metastases. Tumor nodules will be treated with different durations and intensities of CAP before being surgically removed. The resected nodules will be analyzed for tumor vitality.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unraveling Chronic Pain: From Mechanisms and Risks to Diagnosis and Treatment.
Dai X, Wang C, Jiang P, Mei X. · · 2026 · PMID 41930351 · DOI 10.1002/mco2.70685 -
Cold atmospheric plasma-engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity.
Li S, Wang P, Wu Z, Mu Q, et al · · 2026 · PMID 41894511 · DOI 10.1126/sciadv.aeb5894 -
Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.
Yu L, Berner J, Martinet A, Freund E, et al · · 2025 · PMID 41008962 · DOI 10.3390/antiox14091055
Verify or expand the search:
- PubMed search for NCT06796634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Ghent trials
Trials by the same sponsor.
- NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
- NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06796634 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
- Last refreshed: 28 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06796634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing